ArticleTranslational cancer research2026
Complement system-related gene signatures implicated in the recurrence of glioma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioma represents the most common primary malignant tumor of the central nervous system. The complement system, as a key component of the tumor microenvironment (TME), participates in tumor progression by mediating inflammatory responses and immune regulation. However, the specific mechanisms whereby complement system-related genes drive glioma recurrence remain unclear, and robust molecular biomarkers for recurrence prediction are absent. Therefore, this study aims to explore how these genes facilitate glioma progression and recurrence, and to construct a gene signature for recurrence risk prediction. Methods: By analyzing data from public databases Genotype-Tissue Expression (GTEx) and Chinese Glioma Genome Atlas (CGGA) and employing differential expression analysis, univariate Cox regression, multivariate Cox regression, and Bioinformatic regression analyses, we identified six core genes ( Results: Patients in the high-risk group exhibited significantly shorter overall survival (OS). At the mechanistic level, the expression of core genes was potentially closely associated with the Conclusions: This study provides a novel complement system-related gene-based predictive model for glioma recurrence, which may provide a potential biomarker for prognosis assessment and personalized treatment, as well as new insights into the role of the complement system in the immune microenvironment of glioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.